A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Running, not enrolling · Phase 2

Conditions studied: Hepatocellular Carcinoma

In brief

The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.

Key facts

Study ID

NCT06679985

Run by

Coherus Oncology, Inc.

People needed

72

Starts

2024-12-20

Expected to finish

2027-09-01

Last updated by the study team

2026-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Has received prior systemic therapy for HCC.
• Has previously received an anti-IL-27 antibody (Ab) or anti-IL-27-targeted therapy.
• Has known fibrolamellar HCC histology, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
• Has moderate or severe ascites.
• Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).
• Additional protocol-defined inclusion/exclusion criteria apply.

Where it is running

• Mayo Clinic - Scottsdale — Scottsdale, Arizona, United States
• University of Arizona - Cancer Center — Tucson, Arizona, United States
• Beverly Hills Cancer Center — Beverly Hills, California, United States
• City of Hope — Duarte, California, United States
• City of Hope at Irvine Lennar — Irvine, California, United States
• Cancer & Blood Specialty Clinic — Lakewood, California, United States
• USC Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Sarcoma Oncology Center — Santa Monica, California, United States
• Mayo Clinic - Jacksonville — Jacksonville, Florida, United States
• The Winship Cancer Institute Emory University — Atlanta, Georgia, United States
• Mountain States Tumor Institute at St. Luke's Regional Medical Center — Boise, Idaho, United States
• University of Kansas Cancer Center — Kansas City, Kansas, United States
• UofL Health Brown Cancer Center — Louisville, Kentucky, United States
• University of Mississippi Medical Center — Jackson, Mississippi, United States
• Christus St. Vincent Regional Medical Center — Santa Fe, New Mexico, United States
• David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Montefiore Medical Center — The Bronx, New York, United States
• University of North Carolina (UNC) - Chapel Hill — Chapel Hill, North Carolina, United States
• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
• The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James) — Columbus, Ohio, United States
• University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
• Prisma Health Cancer Institute — Greenville, South Carolina, United States
• Virginia Cancer Specialists — Fairfax, Virginia, United States
• Virginia Oncology Associates — Norfolk, Virginia, United States
• UW Carbone Cancer Center - Cancer Connect — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.